FDA Inspection
Medefil IncorporatedMedefil Incorporated – FDA Inspection, Feb 2, 2024
Record Details
This FDA Inspection record concerns Medefil Incorporated, with an inspection on February 2, 2024, issued by the Chicago District Office, covering human drugs.
View Company Profile
ID · 475e69ff-287b-431d-816c-213239b5f140
Inspection Facts
- Inspection number
- 1230282
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
5- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.25(a)Training , Education , Experience overall
- 21 CFR 211.42(c)(7)Quarantined Drug Products Area
- 21 CFR 211.68(b)Computer control of master formula records
- 21 CFR 314.81(b)(1)(ii)Failure to meet specifications
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Medefil Incorporated
11| Date | Classification | Office | Project area |
|---|---|---|---|
| April 21, 2025 | Not classified | Chicago District Office | |
| March 29, 2018 | VAI | Center for Drug Evaluation and Research | Generic Drug Evaluation |
| June 17, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 15, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 20, 2012 | VAI | Center for Devices and Radiological Health | Compliance: Devices |
Other documents for Medefil Incorporated
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.